Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

On June 17, 2024 Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, reported that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum (Press release, Immix Biopharma, JUN 17, 2024, View Source [SID1234644388]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Stifel 2024 Cell Therapy Forum – Immix Biopharma

Date: Tuesday, July 9, 2024
Presentation: Immix Biopharma to present
Location: Virtual
Investor Meetings: The IMMX Team will be available for institutional investor meetings during the conference.

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!